You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: May 23, 2025

CLINICAL TRIALS PROFILE FOR ACLIDINIUM BROMIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Aclidinium Bromide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00358436 ↗ Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD) Completed AstraZeneca Phase 3 2006-08-01 To evaluate the efficacy and safety of LAS 34273 compared to placebo in patients with moderate to severe COPD during one year of treatment.
NCT00363896 ↗ A Trial Assessing LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD) Completed AstraZeneca Phase 3 2006-07-01 To evaluate the efficacy and safety of LAS 34273 compared to placebo in patients with moderate to severe COPD during one year of treatment.
NCT00435760 ↗ Clinical Trial to Assess Rate of Onset of Bronchodilator Action in Severe Stable Chronic Obstructive Pulmonary Disease (COPD) Patients Completed AstraZeneca Phase 3 2007-02-01 This trial evaluates the rate of onset of bronchodilator action of aclidinium bromide compared to placebo and tiotropium in patients with severe COPD after a single dose treatment.
NCT00500318 ↗ A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Completed AstraZeneca Phase 3 2007-07-01 This study evaluated the effect of inhaled aclidinium bromide on exercise endurance and in reducing resting and dynamic lung hyperinflation in patients with moderate to severe COPD. It was 9 weeks in duration, consisting of; a 2-week run-in period, 6 weeks of double-blind treatment, and a 1-week follow-up phone call. All patients meeting the eligibility criteria were randomized to one of two treatment groups: aclidinium bromide or placebo.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Aclidinium Bromide

Condition Name

Condition Name for Aclidinium Bromide
Intervention Trials
Chronic Obstructive Pulmonary Disease 13
Chronic Obstructive Pulmonary Disease (COPD) 13
Pulmonary Disease, Chronic Obstructive 7
COPD 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Aclidinium Bromide
Intervention Trials
Pulmonary Disease, Chronic Obstructive 36
Lung Diseases 35
Lung Diseases, Obstructive 31
Chronic Disease 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Aclidinium Bromide

Trials by Country

Trials by Country for Aclidinium Bromide
Location Trials
United States 401
Canada 50
Germany 12
Australia 11
United Kingdom 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Aclidinium Bromide
Location Trials
South Carolina 15
North Carolina 15
Florida 15
Arizona 14
Texas 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Aclidinium Bromide

Clinical Trial Phase

Clinical Trial Phase for Aclidinium Bromide
Clinical Trial Phase Trials
Phase 4 9
Phase 3 20
Phase 2 9
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Aclidinium Bromide
Clinical Trial Phase Trials
Completed 34
Recruiting 3
Withdrawn 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Aclidinium Bromide

Sponsor Name

Sponsor Name for Aclidinium Bromide
Sponsor Trials
AstraZeneca 34
Menarini Group 2
Parexel 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Aclidinium Bromide
Sponsor Trials
Industry 44
Other 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Aclidinium Bromide: Clinical Trials, Market Analysis, and Projections

Introduction

Aclidinium bromide is a long-acting muscarinic antagonist (LAMA) widely used in the treatment of chronic obstructive pulmonary disease (COPD). This article provides an update on the clinical trials, market analysis, and future projections for this drug.

Clinical Trials Overview

Efficacy, Safety, and Tolerability

A significant clinical trial (LAS-MD-38) evaluated the efficacy, safety, and tolerability of aclidinium bromide in patients with moderate to severe COPD. This Phase 3, randomized, double-blind, placebo-controlled study involved 544 patients and compared two doses of aclidinium bromide (200 μg and 400 μg) with a placebo over 12 weeks, followed by a 40-week evaluation of the higher dose. The study aimed to assess the drug's impact on lung function and patient outcomes[1].

Combination Therapy with Formoterol

Another pivotal Phase III clinical trial (ACLIFORM/COPD) investigated the efficacy and safety of fixed-dose combinations of aclidinium bromide and formoterol fumarate. This study, conducted in 22 countries, involved 1729 patients with moderate to severe COPD and demonstrated statistically significant improvements in lung function compared to monotherapy with either drug. The combination therapy showed a favorable safety profile, with common adverse events such as nasopharyngitis and back pain being comparable to those in the placebo group[3].

Cardiovascular Safety

The ASCENT-COPD trial, a Phase IV study, focused on the cardiovascular safety and efficacy of aclidinium bromide in patients with COPD and increased cardiovascular risk. This multicenter, randomized, placebo-controlled trial involved 3630 patients and found that aclidinium bromide was noninferior to placebo in terms of major adverse cardiovascular events (MACE) over three years. Additionally, the study showed a significant reduction in the annual rate of COPD exacerbations and exacerbations requiring hospitalization[4].

Market Analysis

Current Market Size and Growth

The global aclidinium bromide market was valued at approximately USD 600 million in 2023. Market projections indicate that it is expected to grow to around USD 1.1 billion by 2032, driven by increasing demand for effective COPD treatments and the expanding global healthcare market[5].

Market Trends and Drivers

Key drivers of the aclidinium bromide market include the rising prevalence of COPD, advancements in inhaler technology, and the growing need for combination therapies that offer improved lung function and reduced exacerbations. The market is also influenced by regulatory approvals and the competitive landscape, with companies like Almirall and Forest Laboratories playing significant roles[2][5].

Regional Analysis

The market for aclidinium bromide is expected to be dominated by regions with high COPD prevalence, such as North America and Europe. These regions are anticipated to drive the market growth due to better healthcare infrastructure and higher adoption rates of advanced respiratory treatments[2].

Competitive Landscape

The competitive landscape of the aclidinium bromide market is characterized by the presence of major pharmaceutical companies. Almirall and Forest Laboratories, in particular, have been instrumental in developing and marketing aclidinium bromide products, including the combination therapy with formoterol. The market is also subject to competition from other LAMA and LABA products, as well as emerging therapies[3][5].

Projections and Future Outlook

Market Size Projections

The aclidinium bromide market is projected to grow at a significant CAGR from 2025 to 2032, driven by the increasing demand for effective COPD treatments and the expanding use of combination therapies. The market size is expected to reach USD 1.1 billion by 2032, indicating a substantial growth trajectory[5].

Technological Advancements

Advancements in inhaler technology, such as the Genuair® (Pressair™ in the USA) device, are expected to enhance the delivery and efficacy of aclidinium bromide. These technological improvements will likely contribute to the drug's market growth and patient adherence[3].

Regulatory Environment

Regulatory approvals and updates will continue to play a crucial role in the market dynamics of aclidinium bromide. Successful clinical trials and favorable regulatory outcomes will support the drug's continued use and expansion into new markets[4].

Key Takeaways

  • Clinical Efficacy: Aclidinium bromide has demonstrated significant efficacy in improving lung function and reducing COPD exacerbations in various clinical trials.
  • Safety Profile: The drug has shown a favorable safety profile, including in patients with increased cardiovascular risk.
  • Market Growth: The global aclidinium bromide market is projected to grow substantially, driven by increasing demand and technological advancements.
  • Combination Therapy: The combination of aclidinium bromide with formoterol offers a new treatment option for COPD patients, enhancing lung function and reducing exacerbations.
  • Regulatory Environment: Regulatory approvals and ongoing clinical trials will continue to shape the market and usage of aclidinium bromide.

FAQs

What is the primary use of aclidinium bromide?

Aclidinium bromide is primarily used for the maintenance treatment of chronic obstructive pulmonary disease (COPD).

What are the common adverse events associated with aclidinium bromide?

Common adverse events include nasopharyngitis, back pain, pneumonia, urinary tract infections, and upper respiratory tract infections[3][4].

How does the combination of aclidinium bromide and formoterol benefit COPD patients?

The combination therapy offers improved lung function and reduced COPD exacerbations compared to monotherapy with either drug, providing a new treatment option for patients[3].

What is the projected market size of aclidinium bromide by 2032?

The global aclidinium bromide market is expected to reach around USD 1.1 billion by 2032[5].

What are the key drivers of the aclidinium bromide market?

Key drivers include the rising prevalence of COPD, advancements in inhaler technology, and the growing need for effective combination therapies[2][5].

Sources

  1. AstraZeneca Clinical Trials: "Efficacy, Safety, and Tolerability of aclidinium bromide in the treatment of moderate to severe, stable Chronic Obstructive Pulmonary Disease".
  2. Cognitive Market Research: "Global Aclidinium Bromide Market Report 2024 Edition".
  3. BioSpace: "Forest Laboratories, Inc. and Almirall Report Positive COPD Drug Data".
  4. JAMA Network: "Effect of Aclidinium Bromide on Major Cardiovascular Events and Exacerbations in Patients With Chronic Obstructive Pulmonary Disease".
  5. DataIntelo: "Aclidinium Bromide Market Research Report 2032".
Last updated: 2024-12-31

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.